0001209191-22-008246.txt : 20220209 0001209191-22-008246.hdr.sgml : 20220209 20220209200124 ACCESSION NUMBER: 0001209191-22-008246 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220204 FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boyer David W. CENTRAL INDEX KEY: 0001909817 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 22609091 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-02-04 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001909817 Boyer David W. 12780 EL CAMINO REAL SAN DIEGO CA 0 1 0 0 Chief Corp. Affairs Officer Common Stock 2075 D Incentive Stock Option 89.23 2029-10-01 Common Stock 4480 D Non-Qualified Stock Option 89.23 2029-10-01 Common Stock 43724 D Incentive Stock Option 102.90 2030-02-06 Common Stock 479 D Non-Qualified Stock Option 102.90 2030-02-06 Common Stock 11024 D Incentive Stock Option 117.63 2031-02-08 Common Stock 1281 D Non-Qualified Stock Option 117.63 2031-02-08 Common Stock 33754 D Incentive Stock Option 79.02 2032-01-31 Common Stock 1190 D Non-Qualified Stock Option 79.02 2032-01-31 Common Stock 55907 D Restricted Stock Unit Common Stock 10927 D Restricted Stock Unit Common Stock 1823 D Restricted Stock Unit Common Stock 5314 D Restriced Stock Unit Common Stock 8384 D Option granted October 1, 2019 and vests at 25% upon first anniversary (October 1, 2020) and remaining 75% vesting in 36 equal monthly installments beginning November 1, 2020. Option granted February 6, 2020 and vests monthly over four years. Option granted February 8, 2021 and vests monthly over four years. Option granted January 31, 2022 and vests monthly over four years. 1/4 of the Restricted Stock Units vested on October 1, 2020 and October 1, 2021. The remaining units vest equally on each of October 1, 2022, October 1, 2023. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. 1/4th of the Restricted Stock Units vested on February 6, 2021. The remaining units vest equally on each of February 6, 2022, February 6, 2023, February 6, 2024. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, January 26, 2026. /s/ David Boyer 2022-02-09 EX-24 2 attachment1.htm EX-24 DOCUMENT

LIMITED POWER OF ATTORNEY - SECURITIES LAW COMPLIANCE

The undersigned, as an officer of Neurocrine Biosciences, Inc. (the
"Corporation"), hereby constitutes and appoints, jointly and severally Kevin C.
Gorman, Matt Abernethy, and Darin Lippoldt, each of them, the undersigned's true
and lawful attorney-in-fact and agent, each with the power of substitution for
him in any and all capacities to complete and execute such Forms 144, advisable
pursuant to Rule 144 promulgated under the Securities Act of 1933 (as amended)
and Forms 3, 4, and 5 advisable pursuant to section 16 of the Securities
Exchange Act of 1934, and other forms as such attorney shall in his or her
discretion determine to be required by the rules and regulations promulgated
thereunder, or any successor laws and regulations, as a consequence of the
undersigned's ownership, acquisition or disposition of securities of the
Corporation, and to do all acts necessary in order to file such forms with the
Securities and Exchange Commission, any securities exchange or national
association, the Corporation and such other person or agency as the attorney
shall deem appropriate. The undersigned hereby ratifies and confirms all that
said attorneys-in-fact and agents shall do or cause to be done by virtue hereof.

This Limited Power of Attorney is executed at San Diego California, as of the
date set forth below

/s/ David W. Boyer
(Signature)

Date: February 9, 2022